Last Updated : May 17, 2024
The latest CADTH Reimbursement Review reports are posted to this page. CADTH reimbursement reviews are comprehensive assessments of the clinical effectiveness and cost-effectiveness, as well as patient and clinician perspectives, of a drug or drug class. The assessments inform non-binding recommendations that help guide the reimbursement decisions of Canada's federal, provincial, and territorial governments, with the exception of Quebec. Implementation advice and funding algorithms are provided where applicable.
Brand Name | Generic Name | Therapeutic Area Sort descending | Recommendation Type | Project Status | Date Submission Received | Date Recommendation Issued |
---|---|---|---|---|---|---|
Volibris | Ambrisentan | Pulmonary arterial hypertension (WHO class II and III) | List with clinical criteria and/or conditions | Complete | ||
Revatio | Sildenafil citrate | Pulmonary arterial hypertension (WHO class II and III) | List in a similar manner | Complete | ||
Uptravi | Selexipag | Pulmonary arterial hypertension (WHO class II and III) | Reimburse with clinical criteria and/or conditions | Complete | ||
TBC | sotatercept | Pulmonary arterial hypertension (WHO group 1) | Active | |||
Adempas | Riociguat | Pulmonary arterial hypertension (WHO group 1) | List with clinical criteria and/or conditions | Complete | ||
Darzalex | Daratumumab | Rd for MM | Reimburse with clinical criteria and/or conditions | Complete | ||
N/A | bevacizumab and lomustine | Recurrent glioblastoma multiform | Reimburse with clinical criteria and/or conditions | Complete | ||
Keytruda | pembrolizumab | recurrent, or metastatic cervical cancer | Reimburse with clinical criteria and/or conditions | Complete | ||
Epkinly | epcoritamab | Relapsed or refractory diffuse large B-cell lymphoma | Active | |||
Columvi | glofitamab | Relapsed or refractory diffuse large B-cell lymphoma | Reimburse with clinical criteria and/or conditions | Complete |